Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Anhydrous Tolmetin Sodium
2. Anhydrous, Tolmetin Sodium
3. Dihydrate Tolmetin Sodium
4. Mcn 2559
5. Mcn-2559
6. Mcn2559
7. Sodium Anhydrous, Tolmetin
8. Sodium, Tolmetin
9. Tolectin
10. Tolmetin
11. Tolmetin Sodium Anhydrous
12. Tolmetin Sodium, Anhydrous
13. Tolmetin Sodium, Dihydrate
1. 35711-34-3
2. Sodium Tolmetin
3. Tolmetin Sodium Anhydrous
4. Tolmetin (sodium)
5. Sodium 2-(1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl)acetate
6. Sodium 1-methyl-5-(4-methylbenzoyl)-1h-pyrrole-2-acetate
7. Tolmetin Sodium Salt Dihydrate
8. Chebi:9619
9. Sodium;2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetate
10. Sodium 1-methyl-5-p-toluoylpyrrole-2-acetate
11. Wl259637kx
12. Toleclin
13. 1h-pyrrole-2-acetic Acid, 1-methyl-5-(4-methylbenzoyl)-, Sodium Salt
14. Tolectin Ds
15. Tolectin 600
16. Einecs 252-687-3
17. Tolmetin Sodium Salt
18. Nsc-757341
19. Mcn-2559-21-98
20. Unii-wl259637kx
21. 1-methyl-5-(p-toluoyl)-2-pyrroleacetic Acid
22. Spectrum1500582
23. Schembl1477674
24. Chembl1200613
25. Dtxsid2091546
26. Hms500k15
27. Hy-b1799a
28. Tolmetin Sodium [who-dd]
29. Hms1921e19
30. Hms2092o03
31. 1h-pyrrole-2-acetic Acid, 1-methyl-5-(p-toluoyl)-, Sodium Salt
32. Ccg-39123
33. Akos015901707
34. Akos015961034
35. Ncgc00094796-01
36. Ncgc00094796-02
37. Ac-12807
38. Cs-0013840
39. C02328
40. 4-amino-2-methoxy-5-mercaptobenzoicacid
41. Ab01566945_01
42. W-110866
43. Q27108450
44. Sodium [1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl]acetate
45. 1h-pyrrole-2-acetic Acid, 1-methyl-5-(4-methylbenzoyl)-, Sodium Salt (1:1)
Molecular Weight | 279.27 g/mol |
---|---|
Molecular Formula | C15H14NNaO3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 4 |
Exact Mass | 279.08713759 g/mol |
Monoisotopic Mass | 279.08713759 g/mol |
Topological Polar Surface Area | 62.1 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 353 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Tolmetin sodium |
Drug Label | Each capsule, for oral administration, contains 492 mg of tolmetin sodium (as the dihydrate), equivalent to 400 mg of tolmetin. Each capsule contains 36 mg (1.56 mEq) of sodium. Each capsule contains the following inactive ingredients: colloidal sili... |
Active Ingredient | Tolmetin sodium |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 200mg base; eq 600mg base; eq 400mg base |
Market Status | Prescription |
Company | Teva; Mutual Pharm; Mylan |
2 of 2 | |
---|---|
Drug Name | Tolmetin sodium |
Drug Label | Each capsule, for oral administration, contains 492 mg of tolmetin sodium (as the dihydrate), equivalent to 400 mg of tolmetin. Each capsule contains 36 mg (1.56 mEq) of sodium. Each capsule contains the following inactive ingredients: colloidal sili... |
Active Ingredient | Tolmetin sodium |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 200mg base; eq 600mg base; eq 400mg base |
Market Status | Prescription |
Company | Teva; Mutual Pharm; Mylan |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?